Contribute Try STAT+ Today

The pandemic has driven unprecedented demand for remote patient monitoring tools. But for all their tech-savvy convenience, they have yet to overcome major barriers that prevent their adoption among larger swaths of the U.S. population.

Once dominated by bulky devices designed for patients with a narrow set of severe chronic disorders, the RPM space has boomed in recent years, with tech giants and medical startups racing to develop everything from virtual diagnostics to health trackers. But the field still faces several big hurdles to reach its true market potential, from limited internet and device access among rural and low-income populations to public wariness around new tools and looming concerns about privacy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.